ADORA2A and sarcoma: Using an A2aR-null mouse model, several melanoma and T cell lymphoma lines were rejected in a CD8+T cell dependent manner, and addition of a pharmacologic blockade of A2aR could enhance T cell mediated tumor regression in a sarcoma and LL-LCMV tumor model (100).